CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 60 enrolled
Drug / intervention
2'-Fucosyllactose +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06547801
NCT06547801N/ACompleted

Effects of Human Milk Oligosaccharide Ingestion on Weight Loss and Markers of Health

Advanced Protein Technologies Corporation·interventional·Posted Aug 9, 2024·Updated Aug 14, 2024

In Brief

A clinical study evaluating 2'-Fucosyllactose and Maltodextrin for Weight Loss. Completed, enrolled 60 participants across 1 site.

Detailed Summary

A randomized, double-blind, placebo-controlled, parallel arm study of 2'-fucosyllactose (2'-FL) was conducted in healthy males and females between the ages of 18 and 65 at the time of consent. 2'-FL is one of the most prominent HMOs in human milk. Preclinical studies indicate that 2'-FL feeding is prebiotic, anti-inflammatory, anti-thrombotic, and may reduce skeletal muscle atrophy during energy restriction. The investigators hypothesize that supplementation of 2'-FL affects the preservation of muscle mass, strength, and markers of health during exercise and a hypo-energetic weight loss program. To test this hypothesis, the investigators will compare 3 g/day of 2'-FL with 3 g/day of maltodextrin placebo as a daily supplement.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWeight Loss
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedAug 9, 2024
Enrollment StartMay 4, 2023
Primary CompletionAug 20, 2023
Study CompletionFeb 22, 2024
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 1.9 years ago

Interventions

2'-Fucosyllactosedietary

3 g/day of powder orally once daily

Maltodextrindietary

3 g/day of powder orally once daily